Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer


Background: Hereditary non-polyposis colorectal cancer (HNPCC) is clinically defined by familial clustering of colorectal cancer and other associated tumours. Mutations in DNA mismatch repair genes identified in HNPCC families are usually in one of two HNPCC genes: MLH1 or MSH2. Two other genes (MSH6 and PMS2) are also involved in a minority of cases but are less common. Recent advances in molecular genetic techniques have led to the identification of a new category of HNPCC, characterised by the presence of high microsatellite instability (HMSI-H). This group represents at least two molecular subgroups: microsatellite stable and microsatellite instable. While most studies are based on mutation carriers, the Amsterdam criteria for HNPCC were also applied to families fulfilling the Amsterdam I and Amsterdam II criteria, but without mutations in MLH1 or MSH2. These families may represent a new group of HNPCC patients.

Material and Methods

Patients

Forty-one consecutively registered index patients and their families were included, all fulfilling the Bethesda criteria or the Amsterdam criteria. Of the 41 families, 25 families with truncating mutations in MLH1 or MSH2 (12 novel mutations) and 16 Amsterdam positive families without mutations in these genes and without microsatellite instability were included. By thorough molecular and clinical evaluation of 41 families, two different groups were characterised: group 1, 25 families with truncating mutations in MLH1 or MSH2 (12 novel mutations); and group 2, 16 Amsterdam positive families without mutations in these genes and without microsatellite instability in their corresponding tumours.

Revised version received 9 May 2005
Accepted for publication 10 May 2005
Published online first 14 June 2005

Results

Significant clinical differences between these two groups were found. Firstly, earlier age of onset for all colorectal cancers (median 41 v 55 years; p < 0.001) and all tumours (median 43 v 56 years; p = 0.022) was observed, comparing groups 1 and 2. Secondly, 68% of the index colorectal cancers were localised proximally of the splenic flexure in group 1 compared with 14% in group 2 (p < 0.010). Thirdly, more synchronous and metachronous colorectal (p = 0.017) and extracolorectal tumours (p < 0.001) were found in group 1. Fourthly, a higher colorectal adenoma/carcinoma ratio (p = 0.030) and a tendency towards more synchronous or metachronous adenomas in group 2 (p = 0.084) was observed, indicating a slower progression of adenomas to carcinomas.

Conclusion: These data show that HNPCC includes at least two entities with clinical and molecular differences. This will have implications for surveillance programmes and for cancer research.

Abbreviations: HNPCC, hereditary non-polyposis colorectal cancer; CGH, comparative genomic hybridisation; CIN, chromosomal instability; MSI, microsatellite instability; MSI-H, high microsatellite instability; DHPLC, denaturing high performance liquid chromatography; PCR, polymerase chain reaction

Original study of hereditary non-polyposis colorectal cancer (HNPCC) described a clinical entity of familial clustering of colorectal cancer, according to the Amsterdam criteria. Early onset colorectal cancer with predominantly right sided tumours, marked lymphocyte infiltration, and a high synchronous and metachronous tumour risk have been demonstrated. Identification of microsatellite instability (MSI) in a major subset of tumours and later the detection of germline mutations in DNA mismatch repair genes gave the impression of HNPCC as a molecularly defined hereditary tumour entity. After the introduction of experience based surveillance programmes, it became obvious that there was a significant number of families fulfilling the Amsterdam criteria of HNPCC with neither MSI in their corresponding tumours nor germline mutations in DNA mismatch repair genes. Surveillance strategies in these families cannot be limited to mutation carriers but must be offered to at least all first degree relatives. Regarding these families with the clinical HNPCC syndrome but with no molecular features of high microsatellite instability (MSI-H), it is not yet clear whether they should be managed in the same way as those families harbouring a germline mutation in one of their mismatch repair genes. Amsterdam positive but mutation negative families very often have been classified as clinical HNPCC without indicating that this is probably a molecular and perhaps also a clinically distinct entity harbouring at least two subgroups: microsatellite stable and microsatellite instable tumours.

In this study, we present the clinical features of MSI-H mutation positive compared with mutation negative families with microsatellite stable tumours meeting the Amsterdam criteria in order to better describe this subgroup and make suggestions regarding clinical management and genetic counselling in these families.
gastroenterology of the Universities of Munich. All patients gave written informed consent to take part in this study funded by the German Cancer Aid and approved by the ethics committees.

DHPLC analysis of MLH1, MSH2, and MSH6
All exons of the MLH1, MSH2, and MSH6 gene were amplified using primers previously published.7–9 MLH1 and MSH2 were analysed for all patients whereas MSH6 was analysed additionally for all patients without mutations in MLH1 or MSH2.

DHPLC analysis was carried out on an automated DHPLC device equipped with a DNA separation column (WAVE; Transgenomic, San Jose, California, USA), as published previously.7

Deletion screening
Genomic DNA of patients without truncating point mutations was analysed for exon deletions for all exons of MLH1 and MSH2 using the MLPA kit according to the manufacturer’s instructions (MRC Holland). Polymerase chain reaction (PCR) products were run on an ABI 3100 genetic analyser.

Microsatellite analysis
After microdissection and extraction, mono- and dinucleotide repeat sequences were used for microsatellite analysis following standard procedures.10 11 The polymorphic markers BAT25, BAT26, D2S123, D5S346, and D17S250 were amplified from tumour DNA and from genomic DNA isolated from peripheral blood leucocytes of the respective patients. If the tumours did not reveal a MSI-H phenotype, an extended marker panel including p53, D7S1824, D18S58, TGF βRII, MYCL1, and D10S197 was analysed.12 PCR products were run on an Applied Biosystems 377 DNA sequencer. Samples were judged as MSI-H showing MSI for at least two of the five or four out of 10 loci, as MSI-low with MSI at one out of four or 1–3 out of 10 loci, and as microsatellite stable without MSI.

Immunohistochemistry for MLH1, MSH2, and MSH6
Monoclonal mouse antihuman MSH2 antibody (Calbiochem Oncogene Research Products, Heidelberg, Germany) and

![Figure 1](http://gut.bmj.com/)

**Figure 1** Tumour spectrum of families with truncating mutations in MLH1 or MSH2 (A) and without mutations (B). Tumour diseases of the index patients and those of family members are shown. Hereditary non-polyposis colorectal cancer associated tumour diseases are shown in the shaded areas. *Age of onset, age of the index patient at the time of the first tumour disease; †average family age, sum of the age of onset of all tumour patients in a family divided by the number of patients; A, adenomatous polyp; BC, breast cancer; CC, colorectal cancer; CNS, central nervous system cancer; EC, endometrial cancer; GC, gastric cancer; L, leukaemia; OEC, oesophageal cancer; PAC, pancreatic carcinoma; PC, prostate cancer; PEC, pelvic carcinoma; SBC, small bowel cancer; SC, sebaceous cancer; TC, thyroid cancer; UC, urothelial cancer; UVC, unverified cancer.
MSH6 antibody (Becton Dickinson, Heidelberg, Germany) were used at a dilution of 1:200 or 1:400, respectively. Monoclonal mouse antihuman MLH1 antibody (Zymed, Berlin, Germany) was used at a dilution of 1:80.

Immunohistochemical stainings on microdissected paraffin embedded tissue blocks were performed following standard procedures. Staining pattern for the antibodies was nuclear. A tumour was defined as positive if more than 10% of the tumour cells showed a nuclear staining pattern. A negative staining reaction in tumour cells was only regarded as loss of protein expression in the presence of a positive staining reaction in stromal cells and lymphocytes serving as controls. Specificity of staining was proven by replacement of the primary antibody with the mouse IgG isotype (Southern Biotechnology Associates INC., Birmingham, UK) resulting in a negative staining reaction.

Comparative genomic hybridisation (CGH)
Tumorous and non-tumorous DNA was extracted from paraffin embedded tissue by manual microdissection. Dissected DNA and reference DNA of a healthy donor were labelled by nick translation using fluorescent labelled nucleotides. Equal amounts of both were hybridised with human metaphase chromosomes. A computer based analytical system has been used to evaluate chromosomal gains and losses. The CGH technique was applied as described by Aust and colleagues.

Statistics
Differences in localisation and frequencies of tumour diseases for the MLH1 and MSH2 group as well as for the mutation negative group were analysed using the Mann-Whitney U test. A χ2 test was used to compare the size of the tumour subgroups and age of onset (SPSS software package; SPSS Inc., Chicago, Illinois, USA). Statistical significance was assumed at p<0.05.

RESULTS
Families
We analysed the clinical differences between families with and without mutations in MLH1 or MSH2. We compared 25 families with truncating mutations in MLH1 or MSH2 who were regarded as mutation positive families with 16 Amsterdam positive families without mutations in DNA mismatch repair genes and without MSI (mutation negative families).

Among the 16 Amsterdam positive families without mutations in DNA mismatch repair genes and without MSI, family No 41 showed one gastric and one endometrial cancer apart from two colorectal cancers. Intensive mutation screening with DHPLC for MLH1, MSH2, and MSH6 and deletion screening for MLH1 and MSH2 did not reveal a disease causing mutation in this special case, so the family was judged to be mutation negative. MSH6 was also screened in family No 27 where two colorectal and one endometrial cancer had occurred.

Mutation in MLH1 and MSH2
Twenty different mutations in 25 families were identified. The precise genetic changes in the MLH1 and MSH2 genes of the families are shown in table 1. Of these 25 mutations, 12 were detected in MLH1 and 13 in MSH2, including 14 different new truncating mutations for MLH1 (six) and MSH2 (eight), seven affecting splice sites, six frameshift mutations, and one nonsense mutation. Remarkably, of the 12 truncating mutations found in MLH1, six (50%) affected only two different nucleotides in MLH1.

Microsatellite analysis
Within the group of 25 mutation positive families, we were able to analyse colorectal cancers from 23 families, all showing high grade MSI (for details see table 1). Of these 25 mutations, 12 were detected in MLH1 and 13 in MSH2, including 14 different new truncating mutations for MLH1 (six) and MSH2 (eight), seven affecting splice sites, six frameshift mutations, and one nonsense mutation. Remarkably, of the 12 truncating mutations found in MLH1, six (50%) affected only two different nucleotides in MLH1.

Immunohistochemistry
Within the MSH2 mutation positive families, we were able to analyse tumours for 10 of 13 families. All tumours showed...
The average age of onset for any tumour of onset for all documented cancers diagnosed in the families group however showed 7, 12, and 3 colorectal cancers, in MSH2 (50%). The highest percentage of associated extracolorectal tumours was observed in the MSH2 mutation positive group: endometrial cancer (10%) followed by small bowel cancer (7%), gastric cancer (5%), CNS cancer (3%), breast cancer (2%) and prostate cancer (2%).

### Table 1 Results of microsatellite analysis and immunohistochemistry for patients with truncating mutations in MLH1 or MSH2

<table>
<thead>
<tr>
<th>Pedigree</th>
<th>Exon</th>
<th>Codon/ amino acid change</th>
<th>Nucleotide change</th>
<th>Consequence</th>
<th>MSI quotient†</th>
<th>MLH1 EXP</th>
<th>MSH2 EXP</th>
<th>MSH6 EXP</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>H1</td>
<td>R100X</td>
<td>c.298 C&gt;T</td>
<td>Nonsense</td>
<td>B†</td>
<td>4/5</td>
<td>+</td>
<td>+</td>
<td>ND</td>
</tr>
<tr>
<td>2</td>
<td>H1</td>
<td>9</td>
<td>c.790-1G&gt;A</td>
<td>Splice defect</td>
<td>A II</td>
<td>4/5</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>H1</td>
<td>9</td>
<td>c.790-1G&gt;G</td>
<td>Splice defect</td>
<td>A I</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>4</td>
<td>H1</td>
<td>9</td>
<td>c.790+1delG</td>
<td>Splice defect</td>
<td>A I</td>
<td>6/7</td>
<td>–</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>5</td>
<td>H1</td>
<td>10</td>
<td>c.884+2T&gt;C</td>
<td>Splice defect</td>
<td>A III</td>
<td>5/5</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6</td>
<td>H1</td>
<td>13</td>
<td>c.1463delA</td>
<td>Frameshift A</td>
<td>I</td>
<td>4/5</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>4/7</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>8</td>
<td>H1</td>
<td>13</td>
<td>c.1640insC</td>
<td>Frameshift A</td>
<td>II</td>
<td>5/8</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>9</td>
<td>H1</td>
<td>13</td>
<td>c.1690insC</td>
<td>Frameshift A</td>
<td>II</td>
<td>5/5</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>10</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift A</td>
<td>II</td>
<td>5/5</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>11</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>12</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>13</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>14</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>15</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>16</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>17</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>18</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>19</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>20</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>21</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>22</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>23</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>24</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
<tr>
<td>25</td>
<td>H1</td>
<td>13</td>
<td>c.1490insC</td>
<td>Frameshift B</td>
<td>5/5</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Novel</td>
</tr>
</tbody>
</table>

*MSI quotient, number of unstable microsatellite markers to the number of markers tested.
†Bethesda positive; ††Amsterdam I positive; †††Amsterdam II positive; *Muir Torre. ND, not determined.
EXP, expression of protein in immunohistochemical staining of tumour tissue.

### Comparative genomic hybridisation

CGH experiments were done for tumours from three families (Nos 29, 30, 31) in the mutation negative group. Tumour tissue of the index patient of family No 29 showed losses for chromosomes 2q22, 4q, 6q12-q14, 11q13-q22, 18q, and gains for 13q, 16p, 20q, and 22q. Tumour tissue of the index patient of family No 30 showed losses for chromosome 18q and gains for 13q12-q14, 19q, and 20q. Tumour tissue of the index patient of family No 31 showed gains for chromosomes 7, 13q, 16p, 20q, and 20p11-2-pter, without clearly detectable losses.

### Cancer occurrence

#### Colorectal cancers and adenomas

Colorectal cancer was the most frequently observed tumour, with 141 colorectal cancers in 41 families. The highest numbers of colorectal cancers were found in the mutation negative group (78%), followed by families with truncating mutations in MLH1 (70%), and then families with mutations in MSH2 (50%).

Three families (Nos 2, 12, 25) in the mutation positive group however showed 7, 12, and 3 colorectal cancers, respectively, without any extracolonic cancer occurrence. Age of onset for all documented cancers diagnosed in the families is shown in fig 2. The average age of onset for any tumour disease in the mutation positive families was 42 years compared with 54 years in mutation negative families (p<0.001) (table 2).

Fifty six colorectal cancers were diagnosed in the MLH1 mutation positive group and 33 were diagnosed in the MSH2 mutation positive group. The clinical features of the mutation positive families are shown in figs 1 and 3.

The difference in age of onset within families increased with the number of tumours observed in families and reached a maximum of 50 years in one family. Mean age of onset for 89 colorectal cancers in the mutation positive group was 43.5 years.

Synchronous and metachronous colorectal cancers were found in 9% of mutation positive patients. Fifty three per cent of all index colorectal cancer tumours in the mutation positive group were diagnosed before the age of 40 years compared with only 13% in the mutation negative group, resulting in a significantly earlier age of onset for all colorectal cancers (median 41 v 55 years; p = 0.001) when comparing groups 1 and 2.

There were 12 syn- or metachronous colorectal cancers in the mutation positive group but just one synchronous colorectal cancer in the mutation negative group (p = 0.017).

Localisation of clearly documented colorectal cancer index cases showed a striking difference between the mutation positive and mutation negative families (fig 3). In the mutation positive families, 68% were found proximally and 32% distally of the splenic flexure. In the mutation negative families, apart from 3 (21%) index colorectal cancer tumours proximal to the splenic flexure, all clustered in the sigmoid colon or rectum (p = 0.010). Among 53 colorectal cancers, 20 adenomas were documented in the mutation negative group whereas only 15 adenomas but 89 colorectal cancers were documented in the mutation positive group (p = 0.030) (table 2).

### Extracolonic cancers

The highest percentage of associated extracolorectal tumours was observed in the MSH2 mutation positive group: endometrial cancer (10%) followed by small bowel cancer (7%), gastric cancer (5%), CNS cancer (3%), breast cancer (2%) and prostate cancer (2%).
(3%), and sebaceous cancer (3%). Other tumours (oesophageal, skin, brain, urothelial, etc) were found in 19%. In the MLH1 mutation positive group, endometrial cancer (10%) was followed by gastric cancer (5%), breast cancer (5%), and small bowel cancer (4%). Other tumours were found in 6%.

Comparing the occurrence of cancer types in the MLH1 and MSH2 mutation positive groups, the percentage of tumours was similar for endometrial, gastric, small bowel, and breast cancer but different for others, such as skin, brain, and urothelial tumours which were more frequent in the MSH2 mutation positive group. Comparing the MLH1 and MSH2 mutation positive groups, there was a trend regarding the occurrence of colorectal cancer compared with extracolorectal cancers (p = 0.087).

In the mutation negative group, 78% of the cancers diagnosed were colorectal cancer, followed by endometrial cancer (5%) and gastric cancer (5%). A striking difference was found for the occurrence of syn- or metachronous extracolorectal cancers, with 17 syn- or metachronous extracolorectal cancers in the mutation positive group compared with none in the mutation negative group (p<0.001).

DISCUSSION
High throughput and sensitivity techniques such as DHPLC make it easier to identify mutations in families suspected of having HNPPC.7 Nevertheless, it is important to have pre-selection based on family history.21 22 Selection of families on the basis of the Amsterdam criteria achieves a high rate (approximately 60%) of mutation detection. All of our families underwent genetic counselling with extensive evaluation of their family histories. We analysed MSI,
immunohistochemistry, and the MLH1 and MSH2 genes for all index patients of families fulfilling the Amsterdam criteria, and the MSH6 gene if no mutation was found in MLH1 or MSH2. For families or patients fulfilling the Bethesda criteria, we first performed microsatellite analysis and immunohistochemistry followed by mutation analysis in case of MSI or loss of expression in the tumour tissue. In this way, we identified 25 families with disease causing truncating mutations in MLH1 or MSH2. We also defined 16 families fulfilling the Amsterdam criteria without truncating mutations in DNA mismatch repair genes and without MSI in their corresponding tumours in at least 10 of these families. These 41 families formed the basis for comparison of the clinical features of these two molecular defined entities. The major clinical differences found were age of onset, tumour spectrum, tumour localisation, and tumour progression.

Comparing the mutation positive and mutation negative groups, there was a significantly earlier age of onset for all colorectal tumours (median 41 v 55 years; p \leq 0.001) and for all tumours (median 43 v 56 years; p = 0.022) in the mutation positive group. No difference in the age of onset for colorectal cancer was found between the MLH1 and MSH2 mutation positive groups.

The clinical features in the mutation positive group resembled those of known mutation positive HNPCC patients.\(^25\) The most frequent type of cancer diagnosed was colorectal cancer (63%) followed by endometrial cancer (10%), gastric cancer (5%), and cancer of the small bowel (5%). Other cancer types with typical mutations in DNA mismatch repair genes such as CNS and skin cancer were also observed. In the mutation negative group, we found 78% colorectal cancers, in addition to gastric (5%) and endometrial (5%) cancers. Other associated cancers typical of mutation positive HNPCC patients were not observed. A striking difference between the mutation positive and negative groups was the rate of syn- or metachronous extracolorectal cancer (p<0.001) where none was observed in the mutation negative group.

Wijnen et al\(^{21}\) described a method according to which a low average age of onset, presence of endometrial cancer, and fulfilment of the Amsterdam criteria increased the probability of mutation identification in HNPCC families.\(^7\) This is in agreement with our results with the exception of family Nos 27 and 41 which fulfilled the Amsterdam criteria and showed a tumour spectrum typical of mutation positive families.

Another striking difference between the mutation negative and positive groups was the localisation of colorectal cancers. Within the mutation positive group, 68% of the documented colorectal cancers were found proximal to the splenic flexure, representing distribution over the whole colorectum. In the mutation negative group, 79% of cancers were located distal to the splenic flexure, all in the sigmoid colon and rectum. Hence, approximately 45% of the first colorectal cancers were proximal to the splenic flexure or 46% if metachronous cancers are taken into account. Other studies involving Amsterdam positive families with and without mutations in DNA mismatch repair genes showed 70% of colorectal cancers located proximal to the splenic flexure.\(^25\) The only explanation for this discrepancy is selection bias towards a higher number of Amsterdam positive families without mutations in DNA mismatch repair genes for the purposes of this special study.

Another important difference was the number of adenomas observed in the mutation negative and mutation positive groups. In the second group, apart from 89 colorectal cancers, 12 adenomas (14%) were documented, whereas in the mutation negative group 53 colorectal cancers were found and 20 adenomas (28%). Jass has advocated the “aggressive adenoma” theory that adenomas arise in HNPCC patients as often as in the general population; nevertheless, once formed, they progress to carcinoma faster or more frequently or both than their sporadic counterparts.\(^26\) Jass however did not discriminate between adenomas from mutation positive and mutation negative HNPCC families. The data presented here showed that adenomas in mutation positive patients were less frequent, but there was an almost equal number of colorectal cancers. Therefore, adenomas in mutation positive patients may proceed quickly to carcinomas.

Families with hereditary colorectal cancer without mutations in DNA repair genes, with a later age of onset, and a reduced frequency of associated cancers, seem to represent one subgroup of hereditary colorectal cancers with underlying highly penetrant germline mutations in as yet unknown genes, which overlap with sporadic cases that are caused mainly by exogenic factors and probably low penetrant mutations. Nevertheless, they seem to have the chromosomal instability (CIN) pathway in common. This was highlighted by the CGH data from three tumours in the mutation negative group which showed CIN and aneuploid DNA, typical of sporadic tumours following the CIN pathway.

Within the mutation positive group there was a tendency towards more extracolonic cancers observed in the MSH2 mutation positive group, with only 50% colorectal cancers versus 70% in the MLH1 mutation positive group. Including all gastrointestinal cancers such as gastric, small bowel, and oesophageal cancer, 68% of the cancers were within the
gastrointestinal tract for the MSH2 and 79% for the MLH1 mutation positive group, which was not statistically significant.

Several studies have reported a higher risk of endometrial cancer in MSH2 mutation carriers. In our study, the most frequently diagnosed extracolonic cancer was endometrial cancer, with 10% in the MLH1 and 11% in the MSH2 mutation positive group, which suggests no difference in the risk of endometrial cancer for the two mutated genes.

Two publications describing the clinical differences and similarities between mutation positive and mutation negative families have been published. Bisgaard and colleagues found that families without a mutation fell into two clearly distinguishable subgroups. The major group showed mutations with a significantly lower frequency of multiple colorectal cancers, as well as a lower frequency of HNPCC related cancers. Furthermore, rectal cancer was diagnosed more often and age of onset tended to be later than for mutation carriers. The minor group without mutations generally had the same characteristics as found in affected persons with identified mutations. Because tumours within this last group showed MSI, the authors assumed that deletions within the DNA mismatch repair genes might be causative. The clinical features for the major group of patients without mutations resembled the clinical features of our Amsterdam positive mutation negative group.

Data from Scott and colleagues concur with the results of our study cohort: a significantly later age of onset in the mutation negative group (+5 years; our study +10 years) and more endometrial and stomach cancers in the mutation positive group. However, in the study of Scott et al, statistical significance was reached only for the MLH2 mutation positive group. In this study, missense mutations of uncertain pathology were found in the MLH1 and MSH2 groups. No data concerning localisation of colorectal cancers, MSI, or immunohistochemistry were provided. Missense mutations may increase the average age of onset due to lower penetrance or missing pathology. The pathogenic relevance of these missense variants has yet to be revealed. Furthermore, genomic deletions are not detected by DGGE, which was used for mutation detection by Scott and colleagues.

Our data show that a thorough evaluation of family history, including mutation and microsatellite analysis as well as immunohistochemistry in combination with clinical documentation, allows classification of Amsterdam positive families into two different clinical entities. The major clinical differences were later age of onset, tumour spectrum, distal localisation of colorectal cancers, and slower tumour progression in mutation negative families. Firstly, this may have implications for surveillance programmes, especially in terms of intervals, as there was no evidence of accelerated tumour progression in the mutation negative group. Secondly, cancers in the mutation positive group followed the MIN pathway whereas tumours in the mutation negative group seemed to follow the CIN pathway. The search for the highly penetrant germline mutations causing the cancers in the mutation negative group should be performed for candidate genes in the CIN pathway.

ACKNOWLEDGEMENTS

This work was supported by the German Cancer Aid-Mildred Scheel Foundation.

Y Mueller-Koch and H Vogelsang substantiated the data collected equally, evaluated the data, and prepared the manuscript, including genetic and clinical counselling. R Kopp carried out patient counselling, data collection for the Department of Surgery, and participated in the discussion of the data. P Lohse was responsible for microsatellite analysis at the Ludwig Maximilian University. G Keller was responsible for microsatellite and mutation analysis at the University of Politechniques. M Musers and I Becker carried out tissue preparation for microsatellite analysis, immunohistochemistry, and histopathological evaluation of tumour and adenoma slides at the Ludwig Maximilian University and University of Politechniques. D Aust was responsible for pathology reports as well as the CGH investigation. M Gross and U Schiemann were responsible for clinical counselling, endoscopic, diagnostic, and surveillance programmes. M Scholz was in charge of the internet platform and database necessary for multicentre documentation. B Kerker, I Daum, and M Grabowski were responsible for microsatellite and mutation analysis in two different laboratories (Ludwig Maximilian University). G Henke was in charge of data collection and data coordination. E Holinski-Feder was the laboratory supervisor at the Ludwig Maximilian University, in charge of the coordination of the whole working group, and together with Y Mueller-Koch and H Vogelsang responsible for manuscript preparation.

Authors’ affiliations

Y Mueller-Koch, J Daum, M Grabowski, B Kerker, G Henke, Institute of Human Genetics, Ludwig Maximilian University, Munich, Germany
H Vogelsang*, Department of Surgery, University of Politechniques, Munich, Germany
R Kopp, Department of Surgery, Ludwig Maximilian University, Munich, Germany
P Lohse, Department of Clinical Chemistry, Ludwig Maximilian University, Munich, Germany
G Keller, I Becker, Department of Pathology, University of Politechniques, Munich, Germany
D Aust, M Musers, Department of Pathology, Ludwig Maximilian University, Munich, Germany
M Gross, U Schiemann, Department of Internal Medicine, Ludwig Maximilian University, Munich, Germany
M Scholz, Sylvia Lawry Centre for Multiple Sclerosis Research, Trium Analysis Online GmbH c/o IMS, University of Politechniques, Munich, Germany
E Holinski-Feder, Institute of Human Genetics, Ludwig Maximilian University, Munich, Germany, and Centre of Medical Genetics, Munich, Germany

*Y Mueller-Koch and H Vogelsang contributed equally to the paper.

REFERENCES

What is the diagnosis?

Question

An 84 year old woman presented with a six hour history of acute abdominal pain, coffee ground vomiting, and altered blood per rectum. Her past medical history included hypertension, atrial fibrillation, and arthritis. On examination she was afebrile, normotensive, but tachycardic. There was generalised abdominal tenderness and guarding with vague localisation towards the right lower quadrant. Rectal examination revealed fresh blood mixed with stool. Blood results were unremarkable. Plain radiographs suggested a degree of small bowel obstruction without evidence of free air. The patient underwent intravenous contrast enhanced 16 detector multislice computed tomography (fig 1). The patient refused surgical exploration and thus was treated conservatively. She subsequently had multiple episodes of melena and died 72 hours after admission.

Question

What is the diagnosis?

See page 1767 for answer

This case is submitted by:

S Harish, A M Groves, A H Freeman
Department of Radiology, Addenbrooke’s Hospital, Cambridge, UK

Correspondence to: Dr A Groves, Radiology Department, Box 219, Addenbrooke’s Hospital, Hills Rd, Cambridge CB2 0QQ, UK; drashleygroves@hotmail.com
doi: 10.1136/gut.2005.071654
Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer


Gut 2005 54: 1733-1740 originally published online June 14, 2005
doi: 10.1136/gut.2004.060905

Updated information and services can be found at:
http://gut.bmj.com/content/54/12/1733

These include:

References
This article cites 30 articles, 11 of which you can access for free at:
http://gut.bmj.com/content/54/12/1733#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Colon cancer (1547)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/